. Author manuscript; available in PMC: 2010 Dec 1.

Published in final edited form as: J Neuroimmunol. 2008 Nov 14;206(1-2):121–124. doi: 10.1016/j.jneuroim.2008.09.017

Table 1.

Clinical summary of sALS patients

Patient ID	Patient age (years)	Patient gender	Duration of illness (months)	ALSFRS-R Score	Therapy
Patient ID	Patient age (years)	Patient gender	Duration of illness (months)	ALSFRS-R Score	Riluzole ^a	NSAIDs ^b
Patient 1	52	M	46	34	yes	no
Patient 2	51	F	19	39	yes	no
Patient 3	63	M	24	19	yes	no
Patient 4	66	M	17	39	yes	yes
Patient 5	48	F	8	33	yes	no
Patient 6	72	M	17	37	yes	no
Patient 7	45	M	16	33	yes	no
Patient 8	52	F	40	29	yes	yes
Patient 9	54	M	9	45	yes	yes
Patient 10	52	F	24	29	yes	no
Patient 11	70	M	17	36	yes	yes
Patient 12	52	M	8	38	yes	yes
Patient 13	59	M	11	42	yes	no
Patient 14	70	M	12	35	yes	yes
Patient 15	53	M	18	35	yes	no
Patient 16	73	F	21	34	yes	no
Patient 17	62	M	26	33	yes	yes
Patient 18	52	F	20	42	yes	no
Patient 19	74	M	29	31	no	yes
Patient 20	63	M	6	37	no	no
Patient 21	66	M	21	34	yes	yes
Patient 22	54	M	22	37	yes	no
Patient 23	58	F	7	37	yes	yes

Fifty milligrams twice daily.

NSAIDs, non-steroidal anti-inflammatory drugs (Aspirin, Ibuprofen, Motrin), standard dose.